# A Study With SAGE-547 for Super-Refractory Status Epilepticus

> **NCT02477618** · PHASE3 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Super-Refractory Status Epilepticus

## Interventions

- **DRUG:** SAGE-547
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02477618
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-07-18
- **Final completion:** 2017-08-11
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477618, "A Study With SAGE-547 for Super-Refractory Status Epilepticus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02477618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*